

EXHIBIT 10

NATIONAL ECONOMIC
RESEARCH ASSOCIATES



Consulting Economists

Preliminary and Unchecked

Privileged and Confidential

Summary of Funding Adequacy

Total Payments	(\$ millions)
Total Nominal Value of Expenditure Notices	\$2,588
...of which Base Payments Constitute	\$2,141
...of which Premium Payments Constitute	\$359
...of which Administrative Costs Constitute	\$89
 Total NPV of Expenditure Notices	 \$1,963
...of which Premium Payments Constitute	\$203
Total NPV of Actual Payouts (Accounting for Deferrals)	\$1,963
 Deferred Payments	
Premium Deferrals	\$0
First Year of Premium Deferral	
Average Number of Years in Deferral	N/A
 Base Deferrals	
First Year of Base Deferral	
Average Number of Years in Deferral	N/A

Notes and Sources

1. A discount rate of 7% is used to calculate the Net Present Value (NPV) of payments. Claims take the same amount of time to be processed as observed for each type of benefit in the RSP. The profile of litigation Facility payouts is the same as the profile of Dalkon Shield litigation payouts. Premium payments accrue during the first 7 years at which point they become due for payment.
2. Payments are deferred only if Expenditure Notices exceed the amount of funding ceilings and rollovers (funds unused in prior years). Premium payments are not considered deferred until after the seven year accrual period. Premium payments are deferred before base payments. The number of years that any particular payment is deferred is measured by the "Average Number of Years in Deferral." Zero deferred payments indicate that the funding ceilings and rollovers are adequate to make all the payments in each year.
3. NPV of Actual Payouts is lower than the NPV of Expenditure Notices to the extent that some payments are deferred as described above.

Preliminary and Unchecked
PV Analysis, PV per Claim, 6/24/99, 7:59 PM, QP

Privileged and Confidential

Estimated Aggregate Present Value Payout per Claim for Canadian, Australian and Domestic Settling Claimants

	Domestic Plan					
	Quebec Sub Fund	Ontario Sub Fund	British Columbia Sub Fund	Australian Sub Fund	Bare	Bare with Premium
Settling Claims	7,626 ¹	2,396 ¹	3,919 ²	3,133 ³		131,928
Nominal BI Benefits (Excl. Increased Severity Fund)	37,250,000	17,000,000 ⁴	24,466,798 ⁴	26,204,300	1,622,634,987	1,850,806,711
Less Other Payments/Administrative Costs	332,889 ⁵	332,889 ⁵	3,870,020 ⁶	2,620,350 ⁷		
Total (Nominal \$)	36,917,111	16,667,111	20,596,778	23,983,870 ⁸	1,622,634,987	1,850,806,711
PV BI Benefits (Excl. Increased Severity Fund) ¹⁰	30,746,294	14,191,349	17,519,439	19,996,943	1,202,151,369	1,371,191,073
Plus Increased Severity ¹¹					13,844,971	
Total (PV \$)	30,746,298	14,191,349	17,519,439	19,996,943	1,216,016,340	1,385,056,044
SFV/Number of Claims	4,032	6,181	4,470	6,382	9,281	10,571
Sub-Fund/Bare Base (Payout per Claim)	43.44%	66.60%	48.17%	68.77%		
Sub-Fund/Bare Premium (Payout per Claim)	38.14%	58.47%	42.29%	60.38%		

Notes:

¹ Only Breast Implant Claims are included in Claim counts and are Canadian Current and Unsettled Payouts of Claim, DCC Only and DCC and Others.

² The number of Registrants in the British Columbia Class Action.

³ The number of Registrants in the Australian Settlement Order.

⁴ The \$190,000 Ontario Raw Materials Fund and \$661,800 BC Raw Materials Fund are taken out of this Payment.

⁵ The minimum fixed Administrative Cost described in the Quebec and Ontario Settlements.

⁶ The Supreme Court appointed class counsel fees and disbursements of 1.5% of the Settlement Amount. Also included is the minimum fixed Administrative Cost of \$200,000 described in the British Columbia Sub-Settlement.

⁷ 10% of the Australian settlement amount.

⁸ Includes class counsel fees.

⁹ Includes Raw Materials Funds.

¹⁰ Computed by multiplying the discount factors from NERA Table, "Scheduled Payment of Settlement Amounts of Sub-Funds" by the Total (Nominal \$).

¹¹ The Domestic Breast Implant Payout proportion of Total Breast Implant Payout is applied to the \$15 million Increased Severity Fund.

n/a/b

Preliminary and Unchecked
Settlement Claims and \$ (All Claim Rates), Payment, 6/22/99, 9:05 PM, OP

Privileged and Confidential

Estimated Nominal Settlement Fund Liability
Breast Implant Benefits
Foreign Claims (RSP Rates)

	Total Claims (1)	Settlement Rates			Discounted Total¹ (7)
		Base Per Claim (2)	Premium Per Claim (3)	Settlement Payout With Premium (6)	
Expedited Release	5,917	2,000		11,834,667	5,795,851
Disease					
Option I: Level I					
A	919	50,000	10,000	55,132,606	26,335,695
B	2,749	20,000	4,000	65,976,159	31,515,434
C/D	2,714	10,000	2,000	32,568,329	15,557,211
Option II: Level II					
SS/SLB					
SS/SLE A	29	250,000	50,000	8,762,872	4,185,841
SS/SLE B	11	200,000	40,000	2,590,699	1,237,523
SS/SLE C	41	150,000	30,000	7,425,656	3,547,081
GCTS/PMDMA	32	110,000	22,000	1,543,150	737,131
GCTS B	21	75,000	15,000	1,929,643	921,750
Rupture	3,391	20,000	5,000	84,768,530	41,514,120
Explant	8,235	5,000		41,174,552	20,164,622
Total	24,039			313,706,862	151,512,257

Notes:

Discount includes Multi-Manufacturer discount of 50% (see calculation below) and aggregate foreign claim discount of 49 %.
(Disclosure Statement, Annex A - 13).

Breakdown of DCC Claims	Claims	Percent of Known Dow Claims	Discount Factor
DCC Only + DCC and Others (non RSP)	32,411	95%	100%
DCC and Others (RSP)	1,678	5%	50%
	34,089	100.00%	0.98

Preliminary and Unchecked

Privileged and Confidential

Opt-out Rate Adjusted for Effect of Enhanced Benefits

RSP Opt-out Rate	(a)	9.1%
Effect of Enhanced Benefits on Opt-out Rate	(b) = (ii)/(i)	0.48
Adjusted for Enhanced Benefits	(c) = (a)*(1-(b))	4.7%

Assumptions

Benchmark opt-out rate based on Dalkon Shield Option III experience	(i)	15%
Decrease in the benchmark opt-out rate due to enhanced benefits	(ii)	7.2%

Notes and Sources

1. RSP Opt-out rate is estimated as the proportion of the RSP manufacturers' combined share of all Global claims represented by the RSP manufacturer claims processed by the RSP claims facility (see separate table).
2. The effect of the Plan's enhanced benefits over the RSP is measured with reference to the Dalkon Shield Option III benefit acceptance experience. The acceptance rates predicted by the Dalkon Shield experience, for relatively similar levels of benefit (i.e. the same fraction of the mean), were determined to establish a benchmark overall acceptance rate — and its complement the opt-out rate — corresponding to the RSP benefit levels. The increase in the benchmark acceptance rate was then measured when the benefits were increased to account for the enhancements of the Plan. The principle enhancements are: wider availability of Option I and Rupture benefits, and supplemental "premium" payments for most benefit categories. These nominal dollar enhancements were deflated and the premium payments discounted to account for timing differences.

Preliminary and Unchecked .

Privileged and Confidential

Breast Implant Settlement Benefit Payments (Nominal \$)

	Total Claims (1) (\$ millions)	Domestic Claims (2) (\$ millions)	Foreign Claims (3) (\$ millions)
Expedited Release	80	74	6
Disease Option I	976	903	73
Increased Severity Fund	25	23	2
Disease Option II	141	131	11
Total Disease	1,142	1,056	86
Rupture	582	540	42
Explant	224	204	20
Total Settlement Benefits	2,027	1,874	154

Notes and Sources

1. Benefit payments are calculated by multiplying the total number of current and future claims in each benefit category by the corresponding base plus premium benefit amounts and adjusting for multi-manufacturer and foreign country discounts.
2. The Nominal value of the Increased Severity Fund is calculated such that the capped \$15M NPV is paid out in full in equal annual payments over the life of the Fund, at a discount rate of 7%. The cost of incremental benefits paid to Option II claims due to increases in disease severity over the life of the plan are accounted for in the claim numbers which are estimated assuming an annual probability for each disease of moving (irreversibly) from each severity level to the next higher level.
3. Total Settlement Benefits exclude associated administrative costs.
4. Totals may not add due to independent rounding.

Preliminary and Unchecked

Privileged and Confidential

Summary of Funding Adequacy

Total Payments	(\\$ millions)
Total Nominal Value of Expenditure Notices	\$2,588
...of which Base Payments Constitute	\$2,141
...of which Premium Payments Constitute	\$359
...of which Administrative Costs Constitute	\$89
 Total NPV of Expenditure Notices	\$1,963
...of which Premium Payments Constitute	\$203
Total NPV of Actual Payouts (Accounting for Deferrals)	\$1,963
 Deferred Payments	
Premium Deferrals	\$0
First Year of Premium Deferral	-
Average Number of Years in Deferral	N/A
 Base Deferrals	\$0
First Year of Base Deferral	-
Average Number of Years in Deferral	N/A

Notes and Sources

1. A discount rate of 7% is used to calculate the Net Present Value (NPV) of payments. Claims take the same amount of time to be processed as observed for each type of benefit in the RSP. The profile of litigation facility payouts is the same as the profile of Dalkon Shield litigation payouts. Premium payments accrue during the first 7 years at which point they become due for payment.
2. Payments are deferred only if Expenditure Notices exceed the amount of funding ceilings and rollovers (funds unused in prior years). Premium payments are not considered deferred until after the seven year accrual period. Premium payments are deferred before base payments. The number of years that any particular payment is deferred is measured by the "Average Number of Years in Deferral." Zero deferred payments indicate that the funding ceilings and rollovers are adequate to make all the payments in each year.
3. NPV of Actual Payouts is lower than the NPV of Expenditure Notices to the extent that some payments are deferred as described above.

四

Calculation of the Effect of Instruments on Opt-out Rate Domestic Credit (FSP) lectures 2010 Opt-out

Pn

Print Uncheck

Arrangements (Source RSP Data, See Separate Table)	
Percent of RSP Claims Reaching \$1,000 Advance:	26.0%
Percent of RSP Claims Reaching \$1,000 Advance:	20.4%
Proportion of Advances Payments Made "In-Kind":	13.6%
Proportion of \$15,000 Advances Payments Overpaid for Employer:	4.7%

Notes and Sources

Calculations are performed for December's claims. RSP claims benefit levels are used as of the time of second round open-out decisions (this means that the "cash-out" benefit has not yet been reproduced) but before end-of-year had occurred. For the portion of them extant on the DCOC decision date, the DCOC decision claim numbers are used (first 100% claims) and before applying an overall rate. The same proportion of claimants are assumed to receive zero benefits because they either fail to pursue their claim or fail to ultimately prove their claim.

* N.B. Differences in RSP vs. DCOC benefits do not account for: 1. DCOC increased specialty benefits; 2. Out-of-pocket needs of families under RSP due to advance payment.

† Benefits are calculated for three years to account for decline in portability & power since the RSP benefits were first offered. Premiums & enhancements are discounted using a 10% discount rate for 7 years to account for the expected delay in the approval of Premiums benefits. See separate table. No discounting is applied to account for the lower NPV of future claims since this effect applies equally to the RSP claim population.

Preliminary and Unchecked

Privileged and Confidential

Opt-out Rate Adjusted for Effect of Enhanced Benefits

RSP Opt-out Rate	(a)	9.1%
Effect of Enhanced Benefits on Opt-out Rate	(b)	=-(b)/(1)
Adjusted for Enhanced Benefits	(c)	=-(b)*(1-(b))

Assumptions

Benchmark opt-out rate based on Dalkon Shield Option III experience	(i)	15%
Decrease in the benchmark opt-out rate due to enhanced benefits	(ii)	7.2%

Notes and Sources

1. RSP Opt-out rate is estimated as the proportion of the RSP manufacturers' combined share of all Global claims represented by the RSP manufacturer claims processed by the RSP claims facility (see separate table).
2. The effect of the Plan's enhanced benefits over the RSP is measured with reference to the Dalkon Shield Option III benefit acceptance experience. The acceptance rates predicted by the Dalkon Shield experience, for relatively similar levels of benefit (i.e. the same fraction of the mean), were determined to establish a benchmark overall acceptance rate -- and its complement the opt-out rate -- corresponding to the RSP benefit levels. The increase in the benchmark acceptance rate was then measured when the benefits were increased to account for the enhancements of the Plan. The principle enhancements are: wider availability of Option I and Rupture benefits, and supplemental "premium" payments for most benefit categories. These nominal dollar enhancements were deflated and the premium payments discounted to account for timing differences.

Preliminary and Unchecked

Privileged and Confidential

Breast Implant Settlement Benefit Payments (Nominal \$)

	Total Claims	Domestic Claims	Foreign Claims
	(1) (\$ millions)	(2) (\$ millions)	(3) (\$ millions)
Expedited Release	80	74	6
Disease Option I	976	903	73
Increased Severity Fund	25	23	2
Disease Option II	141	131	11
Total Disease	1,142	1,056	86
Rupture	582	540	42
Explant	224	204	20
Total Settlement Benefits	2,927	1,874	154

Notes and Sources

1. Benefit payments are calculated by multiplying the total number of current and future claims in each benefit category by the corresponding base plus premium benefit amounts and adjusting for multi-manufacturer and foreign country discounts.
2. The Nominal value of the Increased Severity Fund is calculated such that the capped \$15M NPV is paid out in full in equal annual payments over the life of the Fund, at a discount rate of 7%. The cost of incremental benefits paid to Option II claims due to increases in disease severity over the life of the plan are accounted for in the claim numbers which are estimated assuming an annual probability for each disease of moving (irreversibly) from each severity level to the next higher level.
3. Total Settlement Benefits exclude associated administrative costs.
4. Totals may not add due to independent rounding.

Prefile • Ad Unchecked

Privileged • Confidential

Estimated Distribution of Breast Implant Settlement Benefits
 Domestic Claims (RSP Incident(s) Zero Out-of-Pocket)

Mean Disease		27,081	22,563										
DCC Plan													
Proportion of Claims ²	Total (1)	Domestic Claims ³ (2)	Non-US Claims ⁴ (3)	Non-US Expenditure at ever RSP (4)	Base (5)	Premium (6)	Rupture & Explant (7)	No Rupture & Explant (8)	Total (9)	Rupture & Explant (10)	Explant (11)	DCC Nominal Benefit Levels Inc. Premiums	
* ⁵ (1)(2)(3)(4)(5)(6)													
[e] Total Claims Receiving Benefit													
[f] Rupture and Explant													
[g] Expedited Release	48%	13,679	2,000	2,000	0	10,606	9,273	18,300	34,279	81,142	30,000	5,000	0*
[h] Disease		42,463	36,700*										
[i] Option I Level I													
[j] A	7%	6,006	60,000	10,000	10,000	1,678	1,487	2,842	6,006	50,000	65,000	60,000	
[k] B	22%	17,569	24,000	4,000	4,000	1,020	1,447	4,501	17,569	34,000	29,000	24,000	
[l] C/D	22%	17,740	12,000	2,000	2,000	4,956	4,391	17,740	47,900	17,000	12,000		
[m] Option II Level II													
[n] SS/SL/E													
[o] SS/SL/E A	0.2%	191	300,000	50,000	50,000	53	47	90	191	330,000	305,000	300,000	
[p] SS/SL/E B	0.1%	71	240,000	40,000	40,000	20	17	33	71	270,000	245,000	240,000	
[q] SS/SL/E C	0.3%	270	180,000	30,000	30,000	75	67	125	370	210,000	185,000	180,000	
[r] OCTSP/ADMA	0.1%	76	132,000	22,000	22,000	21	19	36	76	162,000	137,000	132,000	
[s] GCTS/B	0.1%	140	90,000	15,000	15,000	39	35	66	140	120,000	92,000	90,000	
[t] Rupture													
[u] A													
[v] B													
[w] C/D													
[x] Options II Explanted													
[y] Explant													
[z] Total		42,752	1,000	2,000	5,000						\$1,142		
[aa] Implied No-Benefit Rate		100%	146,553								41.0%		

Profits and Uncharted

Profits Confidential

Years
Discount Rate:
Benefit Discount Factor:

2.3%¹¹0.97409481¹²0.97409481¹³

0.924094813

0.924094813

0.54936453¹⁴0.54936453¹⁵

0.54936456

0.54936456

0.54936456

Discounted DCC Benefits

RSP Benefits	Rate ¹¹			Premium ¹²			Total			
	No Rupture		Rupture & Replant		No Rupture or Explant		Rupture & Explant		No Rupture or Explant	
	Rupture & Explant	Explant	Explant	Explant	(15)	(16)	(17)	(18)	(19)	(20)
[4] Total Claims Received Benefit										
[5] Repair and Explant	\$,000 ¹⁵	\$,000 ¹⁶	0	23,332	4,670	0	2,747	0	0	0
[6] Expedited Release	\$,000 ¹¹	\$,000 ¹²	0 ¹⁷	25,221	6,539	1,668	2,747	0	0	27,537
[7] Options										
[8] Options II Level I										
[9] A	103,000 ¹⁸	53,500 ¹⁹	30,000 ¹⁸	70,057	51,573	46,703	8,240	5,194	3,194	78,298
[10] B	53,000 ¹⁸	23,000 ¹⁹	20,000 ¹⁸	42,034	23,352	16,632	4,544	2,197	2,197	46,579
[11] C/D	24,000 ¹⁸	12,000 ¹⁹	10,000 ¹⁸	32,693	14,011	9,341	3,846	1,099	1,099	15,110
[12] Options III Level II										
[13] SSBLE										
[14] SSBLE A	251,000 ¹⁸	251,000 ¹⁹	250,000 ¹⁸	246,876	231,194	231,524	30,215	27,468	27,468	287,091
[15] SSBLE B	203,300 ¹⁸	203,300 ¹⁹	203,000 ¹⁸	210,171	191,459	185,819	24,721	21,975	21,975	224,353
[16] SSBLE C	151,000 ¹⁸	151,000 ¹⁹	150,000 ¹⁸	153,467	144,785	140,114	19,228	16,481	16,481	182,694
[17] OCTSRM/MDA	113,000 ¹⁸	113,000 ¹⁹	110,000 ¹⁸	116,105	107,121	102,750	14,833	12,056	12,056	140,576
[18] GCTS B	74,000 ¹⁸	74,000 ¹⁹	71,000 ¹⁸	93,469	74,723	70,357	10,937	8,240	8,240	104,397
[19] Rupture										
[20] A										
[21] B										
[22] C/D										
[23] Option II										
[24] Expedited										
[25] Explant										
[26] Total										
[27] Implied No-Benefit Rate										

Preliminary and Unchecked/Payment Timing By Percent of RSP/Rupture/6/23/99/9:28 AM/JTM Privileged and Unchecked**Timing of Processed Claims****Type of Claimant:****Rupture**

Year (1)	Current Claims (2)	Future Claim Timing (3)	Claimants as of Beginning of Year		Claims	
			Filing (4)	Remaining Future Claims (5)	Filed Claims Pending (6)	Expenditur e Notices (7)
Effective Date ¹	20,287	0	0	4,705	0	0
1		4,705	20,287	4,705	18,725	1,563
2		4,705	4,705	0	12,897	10,533
3			0	0	1,984	10,913
4			0	0	0	1,984
5			0	0	0	0
6			0	0	0	0
7			0	0	0	0
8			0	0	0	0
9			0	0	0	0
10			0	0	0	0
11			0	0	0	0
12			0	0	0	0
13			0	0	0	0
14			0	0	0	0
15			0	0	0	0
16			0	0	0	0
17			0	0	0	0
18			0	0	0	0
19			0	0	0	0
Totals	20,287	9,411	24,993			24,993

Notes and Sources:

Preliminary and Unchecked/Payment Timing By Percent of RSP/Explant/6/23/99/9:28 AM/JTM Privileged and Unchecked

Timing of Processed Claims**Type of Claimant:****Explant**

Year (1)	Current Claims (2)	Future Claim Timing (3)	Claimants as of Beginning of Year		Claims	
			Filing (4)	Remaining Future Claims (5)	Filed Claims Pending (6)	Expenditur e Notices (7)
Effective Date ¹	29,154	0	0	19,820	0	0
1		2,202	29,154	19,820	18,553	10,601
2		2,202	2,202	17,618	4,952	15,803
3		2,202	2,202	15,415	1,670	5,485
4		2,202	2,202	13,213	1,670	2,202
5		2,202	2,202	11,011	1,670	2,202
6		2,202	2,202	8,809	1,670	2,202
7		2,202	2,202	6,607	1,670	2,202
8		2,202	2,202	4,404	1,670	2,202
9		2,202	2,202	2,202	1,670	2,202
10		2,202	2,202	0	1,670	2,202
11			0	0	268	1,401
12			0	0	0	268
13			0	0	0	0
14			0	0	0	0
15			0	0	0	0
16			0	0	0	0
17			0	0	0	0
18			0	0	0	0
19			0	0	0	0
Totals	29,154	22,022	48,974			48,974

Notes and Sources:

Preliminary and Unchecked/Payment Timing By Percent of RSP/Disease Option I/6/23/99/9:28 AM/HMaged and Unchecked

Timing of Processed Claims

Type of Claimant:

Disease Option I

Year (1)	Current Claims (2)	Future Claim Timing (3)	Claimants as of Beginning of Year		Claims	
			Filing (4)	Remaining Future Claims (5)	Filed Claims Pending (6)	Expenditur e Notices (7)
Effective Date ¹	35,895	0	0	10,238	0	0
1		683	35,895	10,238	32,143	3,752
2		683	683	9,555	13,936	18,890
3		683	683	8,873	865	13,754
4		683	683	8,190	865	683
5		683	683	7,508	865	683
6		683	683	6,825	865	683
7		683	683	6,143	865	683
8		683	683	5,460	865	683
9		683	683	4,778	865	683
10		683	683	4,095	865	683
11		683	683	3,413	865	683
12		683	683	2,730	865	683
13		683	683	2,048	865	683
14		683	683	1,365	865	683
15		683	683	683	865	683
16			683	0	865	683
17			0	0	253	611
18			0	0	0	253
19			0	0	0	0
Totals	35,895		10,238	46,133		46,133

Notes and Sources:

Preliminary and Unchecked/Payment Timing By Percent of RSP/Disease Option II/6/23/99/9:28 AM/Unchecked and Unchecked

Timing of Processed Claims**Type of Claimant:****Disease Option II**

Year (1)	Current Claims (2)	Future Claim Timing (3)	Claimants as of Beginning of Year		Claims	
			Filing (4)	Remaining Future Claims (5)	Filed Claims Pending (6)	Expenditur e Notices (7)
Effective Date ¹	670	0	0	157	0	0
1		10	670	157	670	0
2		10	10	147	661	19
3		10	10	136	21	651
4		10	10	126	21	10
5		10	10	115	21	10
6		10	10	105	21	10
7		10	10	94	21	10
8		10	10	84	21	10
9		10	10	73	21	10
10		10	10	63	21	10
11		10	10	52	21	10
12		10	10	42	21	10
13		10	10	31	21	10
14		10	10	21	21	10
15		10	10	10	21	10
16			10	0	21	10
17			0	0	10	10
18			0	0	0	10
19			0	0	0	0
Totals	670		157	827		827

Notes and Sources:

Prell

try and Unchecked Payment Timing By Percent of RSP/\$ by Year and i

see 6/23/999:29 AM UTM

Privileged

Dow Corning
Yearly Value of Disease Claims

Disease	Payouts by Claim as Average Price Per Claim Percentage of Population			
	(1)	(2)	(3)	(4)
	Average Price Per Base	Premium		
A. Expedited	1,865	.6		50.0%
B. Rupture	18,671	4,598		0.0%
C. Explant	4,588	-17		0.0%
D. Disease Option I	17,687	3,471		0.0%
E. Disease Option II	142,880	28,037		0.0%
F. Litigation	17,520	N/A		
LF Provisions		16.81		

Notes and Sources:

¹ Price for base and premium disease option payments are calculated using a weighted average.

Preliminary and Undischarged Payments/Taxes By Percent of NSPS's per Year/Semi-Annual

399927.AMITS

Estimated Timing of Expenditure Notices and Breast Implant Settlement Administration Costs
Domestic Claims & Foreign Claims

Year (1)	Date (2)	Rebate (3)	Exhibit (4)	Expenditure Notices by Type of Claim - Breast Implant Only			Expenditure (5)	Premium (6)	Base (7)	Security Patch (8)	Base (9)	Premium (10)	Base (11)	Premium (12)	Base (13)	Premium (14)	Base (15)	Premium (16)	Total (17)	Average Expenditure Notices Lapsed (withheld) Admin.																
				Disease Notice I																																
				Disease Notice II																																
Effective Date	Date	Rebate	Exhibit	Disease Notice I	Premium	Base	Premium	Base	Security Patch	Base	Premium	Base	Premium	Base	Premium	Base	Premium	Base	Premium	Base	Premium	Total														
1	579,754.254	\$0	50	\$41,642,114	\$64,335,731	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$58,703,677														
2	\$0	\$0	50	\$76,684,395	\$76,496,973	\$0	\$0	\$21,654,473	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$235,447,707														
3	\$0	\$0	50	\$20,374,492	\$21,166,544	\$0	\$0	\$9,298,239	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$40,375,559														
4	\$0	\$0	50	\$10,004,270	\$10,071,684	\$0	\$0	\$1,461,464	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,379,495														
5	\$0	\$0	50	\$10,104,313	\$10,071,684	\$0	\$0	\$1,691,464	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,385,210														
6	\$0	\$0	50	\$10,151,313	\$10,207,144	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,233,671														
7	\$0	\$0	50	\$10,204,494	\$10,250,144	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,200,162														
8	\$0	\$0	50	\$11,403,994	\$10,194,113	\$0	\$0	\$1,912,073	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$17,629,162														
9	\$0	\$0	50	\$10,150,113	\$10,071,684	\$0	\$0	\$1,912,073	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$17,629,162														
10	\$0	\$0	50	\$10,150,113	\$10,071,684	\$0	\$0	\$1,912,073	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$17,629,162														
11	\$0	\$0	50	\$12,071,684	\$12,071,684	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$17,545,373														
12	\$0	\$0	50	\$12,320,207	\$12,071,684	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,389,733														
13	\$0	\$0	50	\$12,071,684	\$12,071,684	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,389,733														
14	\$0	\$0	50	\$12,071,684	\$12,071,684	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,389,733														
15	\$0	\$0	50	\$12,071,684	\$12,071,684	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,389,733														
Excess	\$0	\$0	50	\$12,146,219	\$12,059,369	\$0	\$0	\$1,861,454	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,389,733														
Total	579,754,254	\$466,561,134	\$104,819,944	\$114,919,944	\$114,919,944	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$2,116,010,684														

Notes and Sources

1. Payment Payments are not paid for a period of years (see separate table) according to the terms of the Plan, to ensure funding adequacy prior to the filing of the Trust.

2. Administration Costs are for processing Domestic Plaintiff Settlement Claims. Administration costs for Litigation claims and for other categories of pending claims are included in the amounts reported in the corresponding columns.

